Lilly and Novo Show How AI Is Rewiring Big Pharma

Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug development in ways that are beginning to reshape how fast new medicines reach patients.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Compl ...